EU-FP7 funded project – Grant Agreement number 317246
Translational research (training) in Polycystic Kidney Disease
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is an inherited kidney disorder with a prevalence of more than 1:1000, characterized by the development of renal cysts, slowly progressing towards end-stage renal disease. ADPKD is often associated with extra-renal complications, which can be devastating. Current therapy is directed towards limiting the morbidity and mortality from these complications, whereas effective specific treatments targeting the renal cystic disease are missing. Translational research using innovative approaches from molecular genetics, basic sciences to clinical applications are necessary to unravel the disease mechanism and to develop interventions, monitoring of cystic renal disease progression and to slow down renal cystic disease. In this context, the aim of TranCYST is to offer a multidisciplinary research training program to young researchers for the identification, characterization, and development of novel treatments in ADPKD, to prepare them to become leading scientists who are able to translate fundamental research questions to the clinic and vice versa.
TranCYST is a translational Research and Training Network focussing on Autosomal Dominant Polycystic Kidney Disease.
The Training Network’s mission is to provide a translational multidisciplinary Research Training Programme for talented young researchers, so as to prepare them for leading roles in Polycystic Kidney Disease research in European academia and industry.
The TranCyst network includes 5 European academic groups involved in PKD research with a wide range of expertise ranging from basic scientists to clinical investigators, complemented with 2 private sector (SME) partners with their specific expertise.
All partners apply innovative and state-of-the-art methodologies in their research.
The network covers a broad spectrum of research projects and technologies centred around the aim of translating basic research findings to the clinic. The broad objectives of our training network include:
– The characterization of molecular pathologic changes.
– The validation of preclinical disease models, drug identification and preclinical drug testing.
– The definition of new tools for early prediction and monitoring of cystic renal disease progression, as well as evaluating ongoing clinical trials.
The TranCYST researchers present themselves. View the TranCYST presentation 2014
Summary of the project over the first 24 months (1-12-2012 to 1-12-2014): TranCYST Publishable Summary